Table 1 Demographics and clinical characteristics of the intent to treat study population stratified by ciprofloxacin susceptibility status
| Â | Ciprofloxacin-susceptible NÂ =Â 430 (84.3%) | Ciprofloxacin-resistant NÂ =Â 80 (15.7%) | All NÂ =Â 510 | P value |
|---|---|---|---|---|
Demographics | ||||
 Age, mean +/− SD, (range), years | 62.7 ± 9.1 (33–88) | 61.6 ± 7.6 (42–77) | 62.5 ± 8.9 (33–88) | 0.323 |
 Race, n (%) |  |  |  | 0.101 |
  White | 324 (75.3) | 52 (65.0) | 376 (73.7) |  |
  Black | 68 (15.8) | 15 (18.8) | 83 (16.3) |  |
  Hispanic | 21 (4.9) | 9 (11.2) | 30 (5.9) |  |
  Other | 17 (4.0) | 4 (5.0) | 21 (4.1) |  |
Clinical characteristics | ||||
 Reason for biopsy, n (%) |  |  |  | 0.745 |
  Elevated PSA | 357 (83.0) | 66 (82.5) | 423 (82.9) |  |
  Abnormal DRE | 29 (6.7) | 4 (5.0) | 33 (6.5) |  |
  Both | 27 (6.3) | 5 (6.2) | 32 (6.3) |  |
  Other | 17 (4.0) | 5 (6.2) | 22 (4.3) |  |
 Biopsy result, n (%) |  |  |  | 0.848 |
  Negative | 219 (50.9) | 38 (47.5) | 257 (50.4) |  |
  Prostate cancer | 167 (38.8) | 34 (42.5) | 201 (39.4) |  |
  HGPIN | 44 (10.2) | 8 (10.0) | 52 (10.2) |  |
 History of urinary tract infection, n (%) |  |  |  | 0.004 |
  Yes | 39 (9.1) | 16 (20.0) | 55 (10.8) |  |
  No | 382 (88.8) | 60 (75.0) | 442 (86.7) |  |
  Unknown/missing | 9 (2.1) | 4 (5.0) | 13 (2.5) |  |
 History of urinary retention; n (%) |  |  |  | 0.769 |
  Yes | 33 (7.7) | 6 (7.5) | 39 (7.6) |  |
  No | 354 (82.3) | 64 (80.0) | 418 (82.0) |  |
  Unknown/missing | 43 (10.0) | 10 (12.5) | 53 (10.4) |  |
 FQ usage in prior 2 years, n (%) |  |  |  | 0.921 |
  Yes | 95 (22.1) | 19 (23.8) | 114 (22.3) |  |
  No | 225 (52.3) | 42 (52.5) | 267 (52.4) |  |
  Unknown/missing | 110 (25.6) | 19 (23.8) | 129 (25.3) |  |
 Hospitalized in prior 1 year; n (%) |  |  |  | 0.653 |
  Yes | 42 (9.8) | 6 (7.5) | 48 (9.4) |  |
  No | 374 (87.0) | 73 (91.2) | 447 (87.7) |  |
  Unknown/missing | 14 (3.3) | 1 (1.2) | 15 (2.9) |  |
 Healthcare worker; n (%) |  |  |  | 0.728 |
  Yes | 14 (3.3) | 2 (2.5) | 16 (3.1) |  |
  No | 357 (83.0) | 70 (87.5) | 427 (83.7) |  |
  Unknown/missing | 59 (13.7) | 8 (10.0) | 67 (13.1) |  |
 Charlson comorbidity score; n (%) |  |  |  | 0.693 |
  0 | 348 (80.9) | 68 (85.0) | 416 (81.6) |  |
  1 | 16 (3.7) | 2 (2.5) | 18 (3.5) |  |
  2 | 32 (7.4) | 3 (3.8) | 35 (6.9) |  |
  3–16 | 34 (7.9) | 7 (8.8) | 41 (8.0) |  |